{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=31",
    "query": {
      "intervention": "Intramuscular vaccine",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 835,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:33:00.031Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00829595",
      "title": "Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Bowel Disease",
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2005-05",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829595"
    },
    {
      "nct_id": "NCT05281094",
      "title": "Efficacy and Safety of Two Doses of HIL-214 in Children",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gastroenteritis"
      ],
      "interventions": [
        {
          "name": "HIL-214",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "HilleVax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Months",
        "maximum_age": "5 Months",
        "sex": "ALL",
        "summary": "5 Months to 5 Months"
      },
      "enrollment_count": 3084,
      "start_date": "2022-04-28",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281094"
    },
    {
      "nct_id": "NCT05077137",
      "title": "A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Tetanus Diptheria Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Polio Boost Immunization",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-09-07",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05077137"
    },
    {
      "nct_id": "NCT01984983",
      "title": "Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venezuelan Equine Encephalitis Virus Infection"
      ],
      "interventions": [
        {
          "name": "Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% saline placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ichor Medical Systems Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 42,
      "start_date": "2013-12",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-08-26",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984983"
    },
    {
      "nct_id": "NCT02842866",
      "title": "Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis",
        "Meningococcal Meningitis",
        "Meningococcal Infections"
      ],
      "interventions": [
        {
          "name": "Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "56 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "56 Years and older"
      },
      "enrollment_count": 907,
      "start_date": "2016-07-15",
      "completion_date": "2017-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 35,
      "location_summary": "Chandler, Arizona • Anaheim, California • San Diego, California + 28 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02842866"
    },
    {
      "nct_id": "NCT00845429",
      "title": "Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Orthomyxoviruses",
        "Myxovirus Infection"
      ],
      "interventions": [
        {
          "name": "Influenza virus vaccine - cell-based (2007-2008 Formulation)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza virus vaccine (2007-2008 Formulation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 729,
      "start_date": "2007-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2012-12-19",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 15,
      "location_summary": "Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845429"
    },
    {
      "nct_id": "NCT04006457",
      "title": "Long-Term PF-06651600 for the Treatment of Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2019-07-18",
      "completion_date": "2026-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04006457"
    },
    {
      "nct_id": "NCT00336453",
      "title": "Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "6 Months to 59 Months"
      },
      "enrollment_count": 156,
      "start_date": "2006-10",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2009-12-17",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 3,
      "location_summary": "Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336453"
    },
    {
      "nct_id": "NCT00128219",
      "title": "Prevention of GBS Colonization Via Immunity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta Haemolytic Streptococcal Infection"
      ],
      "interventions": [
        {
          "name": "GBS III-TT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus and diptheria toxoids vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 667,
      "start_date": "2003-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 3,
      "location_summary": "Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128219"
    },
    {
      "nct_id": "NCT06905275",
      "title": "A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3M-052-AF + Alum",
          "type": "BIOLOGICAL"
        },
        {
          "name": "UVAX-1107",
          "type": "BIOLOGICAL"
        },
        {
          "name": "UVAX-1197",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-07-07",
      "completion_date": "2027-07-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-18T23:33:00.031Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • New York, New York • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06905275"
    }
  ]
}